On the stock market since 2006, it operates in the world of health and science. It has 625 employees. Now — the numbers.
This is an established company with proven profits.
If every debt were paid off today, $51.5M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 38 buys and 34 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $17.00 — 142% above today’s price.
It pays out $25.05 per share each year — regular cash for whoever holds the stock.
This stock swings about 4.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
The company’s market value is 148 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, GYRE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GYRE is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (54/100) says the stock isn’t cheap.